RxDoctor Payments Data

Jason Seiden, MD

Pulmonary Disease · Burleson, TXNPI 1215126156

Payments from drug & device makers

$55,069in general payments, 2019–2025

Across 690 payments — averaging $79.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$35K
  • Intuitive Surgical$9K
  • AstraZeneca$2K
  • Veran Medical Technologies, Inc.$1K
  • Boehringer Ingelheim$1K
  • Philips North America LLC$665
  • plus $6K from 35 others

What the payments were for

  • Consulting fees$900%
  • Speaking & faculty fees$32,07558%
  • Travel & lodging$3,3576%
  • Food & beverage$13,19824%
  • Education$6,34912%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$55,069 in reported general payments places this provider in the 85th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$260,647
Medicare patients
701
Services billed
2,372

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate44$592,110
Trelegy ElliptaFluticasone/Umeclidin/Vilanter529$414,810
Breztri AerosphereBudesonide/Glycopyr/Formoterol144$130,731
Fasenra PenBenralizumab21$120,639
Breo ElliptaFluticasone/Vilanterol182$102,431
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr168$102,048
Dupixent PenDupilumab23$95,901
Spiriva RespimatTiotropium Bromide142$90,288
Stiolto RespimatTiotropium Br/Olodaterol Hcl130$86,123
NucalaMepolizumab21$84,879
Incruse ElliptaUmeclidinium Bromide58$28,384
SymbicortBudesonide/Formoterol Fumarate61$21,927
Ambrisentan13$16,451
Combivent RespimatIpratropium/Albuterol Sulfate18$16,072
Albuterol Sulfate HfaAlbuterol Sulfate546$14,121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$1,054$784,592334 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Nucala, Incruse Ellipta$34,627$745,8071,009 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,248$152,658205 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in Burleson

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →